Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
AssigneesUniversity of Maryland, Baltimore, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsScott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
Claims10
A method of treating a depression-related disorder in a human subject in need thereof, comprising administering a therapeutically effective amount of the deuterated GABAA5-NAM compound of Formula Ito the subject:
- wherein R1, R2, and R3 each independently are H or D, with the proviso that at least one of R1, R2 and R3 is D, and wherein R4 and R5 each independently are H or D.
Dependencies are inferred from the claim text.